Cell Growth & Differentiation, Vol 1, Issue 7 325-331, Copyright © 1990 by American Association of Cancer Research

ARTICLES

Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors

OM El-Badry, C Minniti, EC Kohn, PJ Houghton, WH Daughaday and LJ Helman
Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892.

Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and appears to arise from developing striated muscle-forming cells. Since insulin-like growth factor II (IGF-II) is involved in normal muscle growth and maturation and elevated IGF-II mRNA levels have previously been reported in rhabdomyosarcomas, we have been studying the possible role of IGF-II in the unregulated growth and invasive potential of these embryonal tumors. In this study, we demonstrate that 13 of 14 rhabdomyosarcoma tumors express high levels of IGF-II mRNA relative to normal adult muscle and also express mRNA for the type I IGF receptors on their cell surface, the receptor thought to mediate the effects of IGF-II on muscle cells. We have established several rhabdomyosarcoma cell lines in mitogen-free media and demonstrate that these cells express type I IGF receptors on their cell surface and secrete IGF-II into the media. Exogenous IGF-II is able to stimulate cellular motility in these cell lines as assayed in a modified Boyden chamber. Finally, alpha IR-3, a type I receptor antagonist, inhibits the growth of these cell lines in serum-free media but does not inhibit IGF-II-induced motility of these cells. These data suggest that endogenously produced IGF-II functions as an autocrine growth and motility factor in many rhabdomyosarcoma tumors. The mitogenic actions of IGF-II are mediated through a domain of the type I IGF receptor that is blocked by alpha IR-3. IGF-II-induced motility may be mediated through an alternative signaling pathway.

This article has been cited by other articles:

				P. Nanni, G. Nicoletti, A. Palladini, A. Astolfi, P. Rinella, S. Croci, L. Landuzzi, G. Monduzzi, V. Stivani, A. Antognoli, et al. Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4 Mol. Cancer Ther., April 1, 2009; 8(4): 754 - 761. [Abstract] [Full Text] [PDF]

				S. Y. Kim, J. A. Toretsky, D. Scher, and L. J. Helman The Role of IGF-1R in Pediatric Malignancies Oncologist, January 1, 2009; 14(1): 83 - 91. [Abstract] [Full Text] [PDF]

				L. Cao, Y. Yu, I. Darko, D. Currier, L. H. Mayeenuddin, X. Wan, C. Khanna, and L. J. Helman Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody Cancer Res., October 1, 2008; 68(19): 8039 - 8048. [Abstract] [Full Text] [PDF]

				P. J Houghton, J. B Easton, and R. T Kurmasheva mTOR as a Target for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 111 - 120. [Abstract] [Full Text] [PDF]

				F. C. Harwood, L. Shu, and P. J. Houghton mTORC1 Signaling Can Regulate Growth Factor Activation of p44/42 Mitogen-activated Protein Kinases through Protein Phosphatase 2A J. Biol. Chem., February 1, 2008; 283(5): 2575 - 2585. [Abstract] [Full Text] [PDF]

				R. T. Kurmasheva, J. B. Easton, and P. J. Houghton Combined Targeting of mTOR and the Insulin-like Growth Factor Pathway ASCO Educational Book, January 1, 2008; 2008(1): 460 - 464. [Abstract] [Full Text] [PDF]

				F. G. Barr and W. H. Meyer Rhabdomyosarcoma: An Overview of Biology, Clinical Features, and the Current Children's Oncology Group Studies ASCO Educational Book, January 1, 2008; 2008(1): 465 - 470. [Abstract] [Full Text] [PDF]

				K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]

				S. N. Prince, E. J. Foulstone, O. J. Zaccheo, C. Williams, and A. B. Hassan Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor Mol. Cancer Ther., February 1, 2007; 6(2): 607 - 617. [Abstract] [Full Text] [PDF]

				J.-Y. Koo, I. Sohn, S. Kim, and J. W. Lee Structured polychotomous machine diagnosis of multiple cancer types using gene expression Bioinformatics, April 15, 2006; 22(8): 950 - 958. [Abstract] [Full Text] [PDF]

				D. H. Geho, R. W. Bandle, T. Clair, and L. A. Liotta Physiological Mechanisms of Tumor-Cell Invasion and Migration Physiology, June 1, 2005; 20(3): 194 - 200. [Abstract] [Full Text] [PDF]

				K. Scotlandi, M. C. Manara, G. Nicoletti, P.-L. Lollini, S. Lukas, S. Benini, S. Croci, S. Perdichizzi, D. Zambelli, M. Serra, et al. Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors Cancer Res., May 1, 2005; 65(9): 3868 - 3876. [Abstract] [Full Text] [PDF]

				L-T Busund, E Richardsen, R Busund, T Ukkonen, T Bjornsen, C Busch, and H Stalsberg Significant expression of IGFBP2 in breast cancer compared with benign lesions J. Clin. Pathol., April 1, 2005; 58(4): 361 - 366. [Abstract] [Full Text] [PDF]

				M. Zygmunt, T. McKinnon, F. Herr, P.K. Lala, and V.K. M. Han HCG increases trophoblast migration in vitro via the insulin-like growth factor-II/mannose-6 phosphate receptor Mol. Hum. Reprod., April 1, 2005; 11(4): 261 - 267. [Abstract] [Full Text] [PDF]

				J. P. Dutcher Mammalian Target of Rapamycin Inhibition Clin. Cancer Res., September 15, 2004; 10(18): 6382S - 6387S. [Abstract] [Full Text] [PDF]

				B. L. Dake, M. Boes, L. A. Bach, and R. S. Bar Effect of an Insulin-Like Growth Factor Binding Protein Fusion Protein on Thymidine Incorporation in Neuroblastoma and Rhabdomyosarcoma Cell Lines Endocrinology, July 1, 2004; 145(7): 3369 - 3374. [Abstract] [Full Text] [PDF]

				S. Croci, L. Landuzzi, A. Astolfi, G. Nicoletti, A. Rosolen, F. Sartori, M. Y. Follo, N. Oliver, C. De Giovanni, P. Nanni, et al. Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells Cancer Res., March 1, 2004; 64(5): 1730 - 1736. [Abstract] [Full Text] [PDF]

				P. Nanni, G. Nicoletti, C. De Giovanni, S. Croci, A. Astolfi, L. Landuzzi, E. Di Carlo, M. Iezzi, P. Musiani, and P.-L. Lollini Development of Rhabdomyosarcoma in HER-2/neu Transgenic p53 Mutant Mice Cancer Res., June 1, 2003; 63(11): 2728 - 2732. [Abstract] [Full Text] [PDF]

				H. Cui, M. Cruz-Correa, F. M. Giardiello, D. F. Hutcheon, D. R. Kafonek, S. Brandenburg, Y. Wu, X. He, N. R. Powe, and A. P. Feinberg Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk Science, March 14, 2003; 299(5613): 1753 - 1755. [Abstract] [Full Text] [PDF]

				J. D. Ravenel, K. W. Broman, E. J. Perlman, E. L. Niemitz, T. M. Jayawardena, D. W. Bell, D. A. Haber, H. Uejima, and A. P. Feinberg Loss of Imprinting of Insulin-Like Growth Factor-II (IGF2) Gene in Distinguishing Specific Biologic Subtypes of Wilms Tumor J Natl Cancer Inst, November 21, 2001; 93(22): 1698 - 1703. [Abstract] [Full Text] [PDF]

				S. Huang, L. N. Liu, H. Hosoi, M. B. Dilling, T. Shikata, and P. J. Houghton p53/p21CIP1 Cooperate in Enforcing Rapamycin-induced G1 Arrest and Determine the Cellular Response to Rapamycin Cancer Res., April 1, 2001; 61(8): 3373 - 3381. [Abstract] [Full Text]

				W. J. Fredericks, K. Ayyanathan, M. Herlyn, J. R. Friedman, and F. J. Rauscher III An Engineered PAX3-KRAB Transcriptional Repressor Inhibits the Malignant Phenotype of Alveolar Rhabdomyosarcoma Cells Harboring the Endogenous PAX3-FKHR Oncogene Mol. Cell. Biol., July 15, 2000; 20(14): 5019 - 5031. [Abstract] [Full Text]

				J. Khan, M. L. Bittner, L. H. Saal, U. Teichmann, D. O. Azorsa, G. C. Gooden, W. J. Pavan, J. M. Trent, and P. S. Meltzer cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene PNAS, November 9, 1999; 96(23): 13264 - 13269. [Abstract] [Full Text] [PDF]

				H. Hosoi, M. B. Dilling, T. Shikata, L. N. Liu, L. Shu, R. A. Ashmun, G. S. Germain, R. T. Abraham, and P. J. Houghton Rapamycin Causes Poorly Reversible Inhibition of mTOR and Induces p53-independent Apoptosis in Human Rhabdomyosarcoma Cells Cancer Res., February 1, 1999; 59(4): 886 - 894. [Abstract] [Full Text] [PDF]

				R. Dagher and L. Helman Rhabdomyosarcoma: An Overview Oncologist, February 1, 1999; 4(1): 34 - 44. [Abstract] [Full Text]

				H. Hosoi, M. B. Dilling, L. N. Liu, M. K. Danks, T. Shikata, A. Sekulic, R. T. Abraham, J. C. Lawrence Jr., and P. J. Houghton Studies on the Mechanism of Resistance to Rapamycin in Human Cancer Cells Mol. Pharmacol., November 1, 1998; 54(5): 815 - 824. [Abstract] [Full Text]

				N. Lamharzi, A. V. Schally, M. Koppan, and K. Groot Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors PNAS, July 21, 1998; 95(15): 8864 - 8868. [Abstract] [Full Text] [PDF]

				D. Le Roith Insulin-Like Growth Factors N. Engl. J. Med., February 27, 1997; 336(9): 633 - 640. [Full Text] [PDF]

				S Bellusci, G Moens, J. Thiery, and J Jouanneau A scatter factor-like factor is produced by a metastatic variant of a rat bladder carcinoma cell line J. Cell Sci., January 5, 1994; 107(5): 1277 - 1287. [Abstract] [PDF]

				A.P. Feinberg, L.M. Kalikin, L.A. Johnson, and J.S. Thompson Loss of Imprinting in Human Cancer Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 357 - 364. [Abstract] [PDF]

				G. R. Thomas, E. E. Tubb, R. B. Sessions, and K. J. Cullen Growth Factor mRNA Expression in Human Head and Neck Malignant Tumors Arch Otolaryngol Head Neck Surg, November 1, 1993; 119(11): 1247 - 1252. [Abstract] [PDF]

				M. Matthay, J. Thiery, F Lafont, F Stampfer, and B Boyer Transient effect of epidermal growth factor on the motility of an immortalized mammary epithelial cell line J. Cell Sci., January 11, 1993; 106(3): 869 - 878. [Abstract] [PDF]